Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00. In the quarter to June 2026, EPS grew 90.8%, free cash flow grew 11.2% and total debt fell 7.87%, each against the same quarter a year earlier.
Follow CLDI
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
(20.15) | (20.06) | (19.11) | (17.51) |
Depreciation & Amortization |
1.63 | 1.65 | 1.68 | 1.71 | |
Non Cash Items (Other) |
2.32 | 1.86 | 1.47 | 1.09 | |
Accounts Payable Change |
(2.09) | (1.33) | (0.34) | (0.29) | |
Change in other assets and liabilities |
(3.38) | (3.41) | (1.98) | (2.77) | |
Operating Cash Flow |
(21.67) | (21.29) | (18.28) | (17.75) | |
Capital expenditures |
(0.10) | (0.12) | (0.12) | (0.09) | |
Investing cash flow |
(0.10) | (0.17) | (0.17) | (0.14) | |
Repayment/Issuance of Debt (Net) |
(2.48) | (2.49) | (0.87) | (0.52) | |
Equity Repurchase (Common, Net) |
33.93 | 20.80 | 16.09 | 18.08 | |
Other financial activities |
(1.23) | (0.85) | (0.72) | (0.75) | |
Financing cash flow |
30.23 | 17.46 | 14.51 | 16.81 | |
Exchange Rate Adjustment |
(0.01) | 0.03 | 0.01 | 0.00 | |
Change in Cash |
8.48 | (3.99) | (3.93) | (1.09) | |
Beginning Cash |
9.81 | 9.81 | 5.82 | 5.82 | |
Ending Cash |
18.29 | 5.82 | 1.89 | 4.73 | |
Stock Based Compensation |
2.28 | 2.11 | 1.73 | 1.37 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(5.46) | (4.74) | (2.32) | (3.05) | |
Investments Change (Net) |
— | 186.49 | — | — | |
Issuance/Purchase of Shares |
33.93 | 20.80 | 16.09 | 18.08 |